Financial Performance - Revenue for the six months ended December 31, 2025, was RMB 266.8 million, a decrease of 39.5% compared to RMB 441.2 million in the same period of 2024[14]. - Gross profit decreased by 32.7% to RMB 47.4 million from RMB 70.4 million year-on-year[14]. - The operating loss improved to RMB 3.4 million from RMB 7.9 million, a reduction of RMB 4.5 million[14]. - Adjusted EBITDA increased to RMB 3.3 million, up RMB 4.4 million from a loss of RMB 1.1 million in the previous year[14]. - Basic loss per share improved to RMB (6.21) cents from RMB (10.00) cents, a decrease of RMB 3.79 cents[14]. - Loss attributable to owners of the Company for the Period was RMB 6.1 million, an improvement from a loss of RMB 8.0 million in the same period of 2024[60]. - The Group recorded overall revenue of RMB 266.8 million, a decrease of 39.5% compared to RMB 441.2 million for the corresponding period in 2024[60]. - Gross profit for the same period was RMB 47,448,000, down 32.5% from RMB 70,363,000 in 2024[158]. - Operating loss narrowed to RMB 3,406,000 from RMB 7,933,000 year-over-year[158]. - The company reported a comprehensive loss of RMB 6,058,000 for the period, which includes a loss of RMB 8,012,000 for the period and total other comprehensive income of RMB 2,249,000[162]. Liquidity and Financial Position - The current ratio increased to 1.5 from 1.3, indicating improved liquidity[14]. - Cash and cash equivalents significantly increased to RMB 63,096,000 from RMB 13,403,000, indicating improved liquidity[155]. - Net cash flows from operating activities amounted to RMB 21.1 million during the period, compared to RMB 8.7 million for the six months ended December 31, 2024[84]. - The Group had total borrowings from banks of RMB 25.0 million at an interest rate of 3.5% per annum, with a gearing ratio of N/A as of December 31, 2025, compared to 3.7% as of June 30, 2025[92]. - The total financial liabilities as of December 31, 2025, are RMB 25,856,000, slightly down from RMB 26,464,000 as of June 30, 2025[188]. - The financial liabilities due within less than 1 year amount to RMB 5,796,000, a significant increase from RMB 887,000 as of June 30, 2025[188]. Operational Efficiency - Trade receivables turnover days decreased to 29.2 days from 33.4 days, reflecting better collection efficiency[14]. - Inventory turnover days improved to 54.3 days from 57.5 days, indicating more efficient inventory management[14]. - Trade payables turnover days decreased significantly to 50.2 days from 80.6 days, suggesting improved payment terms[14]. - Selling and marketing expenses were RMB 32.8 million, a decrease of 45.3% from RMB 60.0 million in the previous year, accounting for 12.3% of the Group's revenue[74]. - Administrative expenses were RMB 18.1 million, a slight decrease of 2.7% from RMB 18.6 million in the previous year, accounting for 6.8% of the Group's revenue[76]. Market Trends and Strategic Focus - The healthcare industry in China is experiencing structural growth driven by population aging and high prevalence of chronic diseases, with a rising demand for chronic disease management and health foods[21][28]. - The Group is focusing on expanding its traditional retail chain stores and distribution network while implementing "Direct to Patient (DTP) pharmacies" to adapt to industry trends[30][33]. - The introduction of new service models, such as telephone ordering and home delivery, has enhanced overall service coverage and user experience[32][33]. - The Group is actively promoting digital transformation to improve its online operational infrastructure and build a more efficient network service system[34]. - The "new silver-haired generation" (aged 50-70) is increasingly emphasizing preventive health management, influencing market trends towards nutritional supplements and health monitoring devices[27][29]. - The Group is committed to enhancing employee training to optimize service capabilities within its retail chain system[31]. - The healthcare market potential is expected to expand further, driven by policy guidance, technological advancement, and rising health consumption awareness[28]. Corporate Governance and Compliance - The Company aims to expand its presence outside Mainland China to maximize shareholder returns and will evaluate viable options for this expansion[103]. - The Group will enhance its corporate governance practices to ensure compliance with the Corporate Governance Code[112]. - The company has complied with the Corporate Governance Code, with some deviations noted regarding the roles of chairman and CEO[110]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited interim results for the period[120]. Share Capital and Options - The Company issued 30,440,263 shares, representing approximately 27.54% of the enlarged issued share capital, at a subscription price of HK$0.08 per share[116]. - The subscription agreement was approved by shareholders in an extraordinary general meeting held on July 23, 2025[117]. - The company granted a total of 20,000,000 share options in September 2017 and 30,000,000 share options in March 2019 to eligible participants, all of which were accepted[127]. - The total number of share options outstanding as of December 31, 2025, is 2,247,000, with no options exercised during the period[143]. - The company’s share option scheme expired on November 17, 2023, and there are no other share schemes currently in force[145]. Social Responsibility and Community Engagement - The Group actively participated in public welfare activities and health education initiatives to enhance corporate reputation and fulfill social responsibilities[50][56].
大健康国际(02211) - 2026 - 中期财报